Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia

Author:

Khaw Seong Lin12ORCID,Suryani Santi3,Evans Kathryn3,Richmond Jennifer3,Robbins Alissa3,Kurmasheva Raushan T.4,Billups Catherine A.5,Erickson Stephen W.6,Guo Yuelong6,Houghton Peter J.4,Smith Malcolm A.7,Carol Hernan3,Roberts Andrew W.18,Huang David C. S.18,Lock Richard B.3

Affiliation:

1. Walter Eliza Hall Institute of Medical Research, Melbourne, Australia;

2. Royal Children’s Hospital, Melbourne, Australia;

3. Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Australia, Sydney, Australia;

4. Greehey Children’s Cancer Research Institute, University of Texas Health Science Center San Antonio, San Antonio, TX;

5. Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;

6. Research Triangle Institute International, Research Triangle Park, NC;

7. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; and

8. Faculty of Medicine, Dental and Health Sciences, University of Melbourne, Melbourne, Australia

Abstract

Key Points Venetoclax demonstrates potent in vitro and in vivo single-agent activity in MLL-rearranged ALL xenografts. Clinically efficacious BH3-mimetic therapy for other high-risk ALL subtypes is likely to require concurrent BCL-2 and BCL-XL inhibition.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 148 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3